PR Jan 13, 2020
PR Nov 26. 2019
PR Nov 25, 2019
PR Oct 1, 2019
LineaRx’s iCTC Platform for Isolation of Circulating Tumor Cells Shows Superior Correlation over PSA as a Biomarker in Prostate Cancer TrialPR Sept 19, 2019
LineaRx and Takis/Evvivax Anti-Canceer Candidates Demonstrate Tumor ReductionPR Aug 12, 2019
Medicare Coverage of CAR T-Cell Therapy Holds Positive Implications for LineaRxPR Aug 8, 2019
LineaRx Acquires Assets and Intellectual Property of VitatexPR Jul 1, 2019
LineaRx Receives Multiple Purchase Orders for Linear DNA for Use in Therapeutic DevelopmentPR Jun 26, 2019
PR May 21, 2019
LineaRx Anticipates Expansion in Diagnostics Market via Follow-on Order and New Linear DNA Amplicons for Additional AssaysPR Apr 29, 2019
LineaRx Achieves Higher Expression and Survival Rates in Human T Cells Transfected Non-Virally with Linear DNAPR Apr 8, 2019
Applied DNA Subsidiary LineaRx Achieves Biotech Industry First with Anti-CD19 Expression in Human CAR T Cells via Proprietary Non-Viral, Plasmid-Free PlatformPR Mar 1, 2019
Applied DNA Subsidiary LineaRx and Takis/Evvivax Progress Linear DNA for Use as Cancer Vaccine CandidatesPR Dec 4, 2018
LineaRx to Hold Analyst Day Webinar to Announce DNA Vaccine Preclinical Data and Efficacy of In-Licensed CAR T TherapyPR Nov 7, 2018
Applied DNA Subsidiary LineaRx Provides Cost and Quality Advantages to Technogenetics Diagnostic SolutionsPR Oct 16, 2018
Applied DNA Subsidiary LineaRx Licenses CAR T Drug Candidate and Initiates Pre-Clinical Development of Non-viral, Plasmid-free CAR T Manufacturing PlatformPR Oct 1, 2018
LineaRx Secures New RNA Therapeutics Customers for Contract Research ServicesPR Sep 20, 2018
Applied DNA Subsidiary, LineaRx, Inc. Signs Joint Development Agreement with Takis and Evvivax to Develop Linear-DNA Based Anti-Cancer VaccinesShow More